BOSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a ...

– Prioritization of Phase 2-ready clinical-stage programs: RLYB212 for the prevention of FNAIT and RLYB116, a C5 inhibitor for the treatment of patients with complement-mediated diseases – – ...

Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease Akari Therapeutics (AKTX) announces leadership ...

SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (BOLD) (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative ...

Leaders often grapple with the feeling that there simply aren’t enough hours in a day. They want to think strategically, plan for the future and invest time in reflecting on their team’s direction, ...

Genmab A/S(Nasdaq: GMAB) announced today thatit will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab’s strategic focus on the most value‑creating ...

This is a RAPS-SF Executives event exclusive for VP and above. This facilitated roundtable discussion event brings together industry leaders to explore how organizations are navigating two critical ...

New AI-native capabilities help organizations continuously prioritize initiatives, reduce redundancy, and move from idea to execution-ready plans faster. Enterprises aren't short on AI ideas. Business ...

The work of portfolio analysis is becoming ever more demanding. The volume and complexity of the tasks required to create, analyze, edit and report on investment portfolios is rising rapidly.

How often do you stare at your massive to-do list, paralyzed by indecision? Do you also feel like you’re constantly being pulled in a million directions? This is a common struggle — however, there is ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced the prioritization of its portfolio and a 45% workforce reduction to focus resources on its Phase 2-ready ...